MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the presentation of data from its Quinamed® (amonafide dihydrochloride) phase 1/2a dose-escalation study, designed to identify a genotypically optimised dose of Quinamed in heavily pre-treated patients with a variety of solid tumors. The key outcomes from this study were (i) demonstration that dose level could be optimised according to patient genotype, (ii) the drug was well tolerated, with predictable and manageable side effects, and (iii) there was evidence of anticancer activity in several solid tumor types.
